Table 5

Significant variables in the bivariate analysis of patients receiving vs. not receiving antifungals, [n (%)] except where indicated
Total patients (n = 245) Colonised (n = 106) Aspergillosis (n = 139)
Treated (n = 104) Non-treated (n = 141) p Treated (n = 31) Non-treated (n = 75) p Treated (n = 110) Non-treated (n = 29) p
Age (X ± SD) 66.7 ± 15.9 71.4 ± 13.8 0.016 66.0 ± 16.7 70.4 ± 15.7 0.086 66.9 ± 15.8 73.9 ± 6.6 0.001
Days to isolation (X ± SD) 12.3 ± 12.2 7.6 ± 7.6 0.001 8.9 ± 6.6 7.0 ± 6.5 0.096 13.2 ± 13.1 9.1 ± 9.6 0.046
COPD 90 (63.8) 83 (79.8) 0.007 15 (48.4) 58 (77.3) 0.005 75 (68.2) 25 (86.2) 0.064
GOLD III + IV 57 (40.4) 54 (51.9) 0.074 8 (53.4) 32 (58.2) 0.568 49 (65.3) 22 (88.0) 0.041
COPD exacerbation 22 (15.6) 3 (2.9) 0.625 6 (19.4) 29 (38.7) 0.070 56 (50.9) 20 (69.0) 0.082
Severe liver disease 3 (2.1) 8 (7.7) 0.058 1 (3.2) 6 (8.0) 0.671 2 (1.8) 2 (6.9) 0.192
Stroke 4 (2.8) 6 (5.8) 0.332 1 (3.2) 2 (2.7) 1.000 3 (2.7) 4 (13.8) 0.035
APACHE II (X ± SD) 13.8 ± 7.6 12.3 ± 5.6 0.076 12.6 ± 7.5 11.2 ± 5.4 0.291 14.1 ± 7.6 15.1 ± 5.1 0.439
ICU admission 47 (33.3) 11 (10.6) 0.001 10 (32.3) 5 (6.7) 0.001 37 (33.6) 6 (20.7) 0.259
ICU stay (days; X ± SD) 7.6 ± 7.9 10.0 ± 3.4 0.113 2.1 ± 4.8 0.3 ± 1.8 0.014 7.9 ± 8.3 2.0 ± 2.8 0.046
Pleuritic pain 19 (13.5) 6 (5.8) 0.049 2 (6.5) 5 (6.7) 1.00 17 (15.5) 1 (3.4) 0.121
Bronchospasm 66 (46.8) 23 (22.1) 0.001 8 (25.8) 17 (22.7) 0.803 58 (52.7) 6 (20.7) 0.003
Infiltrates (X-ray / CT) 102 (72.3) 47 (45.2) 0.001 18 (58.1) 31 (41.3) 0.137 84 (76.4) 16 (55.2) 0.024
Cavitations (X-ray / CT) 31 (22.0) 7 (6.7) 0.001 1 (3.2) 4 (5.3) 0.642 30 (27.3) 3 (10.3) 0.084
Nodules (X-ray / CT) 48 (34.0) 22 (21.2) 0.027 5 (16.1) 16 (21.3) 0.541 43 (39.1) 6 (20.7) 0.081
Treatment with Quinolones 41 (29.1) 42 (40.4) 0.065 12 (38.7) 27 (36.0) 0.827 29 (26.4) 15 (51.7) 0.009

Barberan et al.

Barberan et al. BMC Infectious Diseases 2012 12:295   doi:10.1186/1471-2334-12-295

Open Data